---

Platinum Opinion

27

Setting Research Priorities for Kidney Cancer

27

Brief Correspondence

31

Benefits and Harms of Treatment of Asymptomatic Bacteriuria: A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel

31

Platinum Priorities

35

Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review

35

Prostate Cancer

52

Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What’s New and What’s Not

52

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer—Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies

54

The Next Generation of Prostate Cancer Risk Calculators

63

Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions

65

Real-time Watchful Surveillance Looks Like Active Waiting

74

Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis

76

Balancing Risks in Prostate-specific Antigen Recurrence: The Fox Versus the Hedgehog

84

Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study

86

Type of Androgen Deprivation Therapy and Risk of Cardiovascular Disease

95

Recreational Physical Activity in Relation to Prostate Cancer–specific Mortality Among Men with Nonmetastatic Prostate Cancer

97

Why Epidemiological Studies of Physical Activity in Prostate Cancer Often Underestimate its Benefits

106

The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report

108

New Prostate Cancer Biomarkers: The Search Continues

116

Bladder Cancer

118

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets

118

Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?

126

Kidney Cancer

128

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

128

Subset Analyses from CheckMate 025: A Challenge to Current Clinical Dogma?

138

Recommendations for the Management of Rare Kidney Cancers

140

Time to Focus on the Rare—Encouraging Progress in the Management of Non–clear Cell Renal Cell Carcinoma

150

Benign Prostatic Hyperplasia

152

Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms

152

One Strategy Does Not Fit All: The Era of Personalised Medicine for the Treatment of Male Lower Urinary Tract Symptoms Is upon Us

164

Andrology

166

Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores

166

Is a Normal Testosterone Level Necessary for Erectile Function?

178

Surgery in Motion

180

Zero-fragment Nephrolithotomy: A Multi-center Evaluation of Robotic Pyelolithotomy and Nephrolithotomy for Treating Renal Stones

180

Words of Wisdom

188

Re: Comprehensive Qualitative Assessment of Urethral Stricture Disease: Toward the Development of a Patient Centered Outcome Measure

188

Re: The Use of Apnea During Ureteroscopy

189

Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-term Oncologic Outcomes in a Shared Equal-access Health System

189

Re: Cytoreductive Nephrectomy for Renal Cell Carcinoma with Venous Tumor Thrombus

190

Re: Adjuvant Chemotherapy vs Observation for Patients with Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy

191

Re: Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle Invasive Bladder Cancer

192

Research Letters

193

Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis

193

Hyperpolarized 1-[¹³C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Androgen Ablation Therapy in Prostate Cancer

194

Letters to the Editor published online

197

Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036

197

Reply to Erfan Ayubi and Saeid Safiri’s Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036.

198

Re: Giovanni Corona, Giulia Rastrelli, Abraham Morgentaler, Alessandra Sforza, Edoardo Mannucci, Mario Maggi. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol 2017;72:1000–11

200

Reply to Eugenio Ventimiglia, Paolo Capogrosso, Walter Cazzaniga, Francesco Montorsi, and Andrea Salonia’s Letter to the Editor re: Giovanni Corona, Giulia Rastrelli, Abraham Morgentaler, Alessandra Sforza, Edoardo Mannucci, Mario Maggi. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol 2017;72:1000–11

202

Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042

204

Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung’s Letter to the Editor re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042

206

Re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide. J Clin Oncol2017;35:2149–56

208

Reply to Julie Steinestel, Christof Bernemann, Andres J. Schrader, and Jochen K. Lennerz’s Letter to the Editor re: Emmanuel S. Antonarakis, Changxue Lu, Brandon Luber, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men with Metastatic Castration-resistant Prostate Cancer Treated with First- and Second-line Abiraterone and Enzalutamide.

210

Re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol 2017;72:942–9

212

Reply to Parham Habibzadeh and Farrokh Habibzadeh’s Letter to the Editor re: Eric A. Klein, Arnon Chait, Jason M. Hafron, et al. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.03.025.

214

Re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50

215

Reply to Jae Heon Kim, Bora Lee, and Benjamin I. Chung’s Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50

216

Re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50

217

Reply to Paolo Capogrosso, Francesco Montorsi, and Andrea Salonia’s Letter to the Editor re: Philipp Mandel, Felix Preisser, Markus Graefen, et al. High Chance of Late Recovery of Urinary and Erectile Function Beyond 12 Months After Radical Prostatectomy. Eur Urol 2017;71:848–50. Late Recovery of Erectile Function After Radical Prostatectomy: Should We Modify the Way of Assessment?

219

Re: Sumanta K. Pal, Guru Sonpavde, Neeraj Agarwal, et al. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. Eur Urol 2017;72:557–64

220

Congress Calendar

222

Acknowledgement to Reviewers

225